<DOC>
	<DOC>NCT02268773</DOC>
	<brief_summary>To compare the combination of acetylsalicylic acid (25 mg) + modified-release dipyridamole (200 mg) bd versus acetylsalicylic acid (75 mg dispersible tablet once daily) in its effect on inhibition of thromboxane B2 formation</brief_summary>
	<brief_title>Effects of Acetylsalicylic Acid Compared With the Combination of Acetylsalicylic Acid + Modified-release Dipyridamole on Serum Thromboxane B2 Formation and Platelet Aggregation in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<mesh_term>Aspirin, Dipyridamole Drug Combination</mesh_term>
	<criteria>Male or female healthy volunteers aged 20 to 50 years Clinically normal medical history Clinically normal findings on physical examination Capable of comprehending and communicating effectively with the investigator and staff and of providing informed consent Willing to give informed consent prior to participation in the trial (i.e. prior to any trialspecific procedures) Any clinically significant disease. (A significant disease is defined as a disease which in the opinion of the investigator may either put the subject at risk because of participation in the study or a disease which may influence the results of the study or the subject's ability to participate in the study) Clinically significant abnormal baseline haematology, blood chemistry or urinalysis findings Serum glutamateoxaloacetate transferase (SGOT) or serum glutamatepyruvate transferase (SGPT) &gt; 80 IU/L, bilirubin &gt; 34 µmol/L or creatinine &gt; 176 µmol/L regardless of clinical condition. Repeat laboratory evaluation will not be conducted in these subjects Use of dipyridamole, aspirin or any nonsteroidal antiinflammatory agent (NSAID) during the previous two weeks Active peptic ulceration or history of peptic ulcer disease Known history of or suspected hypersensitivity to dipyridamole, aspirin, any NSAID or any other component of the test drugs History of any bleeding disorders History of cerebral haemorrhage Resting, seated blood pressure less than 90/60 mmHg Participation in any drug clinical trial within sixteen weeks prior to the start of the trial Any indication of current or previous abuse of alcohol, solvents or drugs Any chronic illness Asthma Requirement for any other medication one month before or during the study Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (e.g. oral contraceptives, intrauterine devices or surgically sterile) were to be excluded Previous participation in the randomisation phase of this clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>